Given emerging data on the role of RS and the recent discrepant treatment in these patients, this study aimed to clarify the practice patterns and the potential benefit of 21-gene testing in BC patients with ER+/HER2− and one to three LNs. This evidence concerns the gene ESR1 and breast cancer.